The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Nov 1999
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialDouble-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.
Fexofenadine hydrochloride (HCl) is a new H(1) antihistamine used twice daily in some countries. ⋯ Once-daily fexofenadine is thus a valuable addition to the nonsedating group of H(1) receptor antagonists currently available for the treatment of seasonal allergic rhinitis.
-
J. Allergy Clin. Immunol. · Oct 1999
Multicenter StudyThe relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program.
Sensitivity and exposure to indoor allergens constitutes a risk factor for the development and persistence of asthma in children. ⋯ Sensitivity to dog or cat dander or Alternaria by skin testing was associated with increased bronchial responsiveness but not decreased lung function in children with mild to moderate asthma. These findings support the important role that sensitization to certain allergens plays in modulating bronchial responsiveness.
-
J. Allergy Clin. Immunol. · Sep 1999
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialMontelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group.
Montelukast, a leukotriene receptor antagonist, and salmeterol, a long-acting beta(2)-receptor agonist, each have demonstrated benefits in the treatment of exercise-induced bronchoconstriction (EIB) in short-term studies. Direct comparisons between these agents in long-term studies are limited. ⋯ The effect of montelukast was greater than that of salmeterol in the chronic treatment of EIB over a period of 8 weeks in patients with mild asthma as demonstrated by effect size, maintenance of effect, and fewer respiratory clinical adverse events during the study period. Montelukast may be a better alternative to salmeterol as a controller agent for the chronic treatment of EIB.
-
J. Allergy Clin. Immunol. · Jun 1999
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialComparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients. ⋯ In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period.
-
J. Allergy Clin. Immunol. · Mar 1999
Randomized Controlled Trial Multicenter Study Clinical TrialRelationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
Many factors, including heredity, atopic status, and environment, have been implicated in the determination of asthma severity. Relatively little is known about the degree to which asthma duration influences asthma severity. ⋯ These data demonstrate that asthma duration is associated with lower lung function, greater methacholine responsiveness, more asthma symptomatology, and greater use of as-needed albuterol, which are all measures of asthma severity. As such, early diagnosis and intervention may be necessary to ameliorate these adverse effects of persistent asthma.